![Ksenija Pavletic](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Ksenija Pavletic
Directeur/Membre du Conseil chez
ODYSSEY THERAPEUTICS, INC.
Profil
Ksenija Aranicki Pavletic is currently Chief Executive Officer at Advesya Ltd. since 2022.
Ksenija is an Independent Director at Odyssey Therapeutics, Inc. starting in 2025.
Ksenija serves as Director at ReproNovo SA, Azafaros BV, and Callio Therapeutics, Inc. Ksenija is also General Partner & Chief Commercial Officer at Jeito Capital SASU since 2024.
Former roles include Director at Release Therapeutics SA from 2020 to 2024, Director-Global Marketing at Merck Serono SA, and Vice-President-Marketing & Business Development at PregLem SA. Education includes an MBA from Webster University and a graduate degree from the University of Zagreb.
Postes actifs de Ksenija Pavletic
| Sociétés | Poste | Début |
|---|---|---|
| ODYSSEY THERAPEUTICS, INC. | Directeur/Membre du Conseil | 01/08/2025 |
Jeito Capital SASU
 Jeito Capital SASU Investment ManagersFinance Jeito Capital is an active manager which seeks investment opportunities in companies located in Europe. The firm targets companies operating in the fields of biotech and biopharma. It provides financing for early stage capital requirements. | Private Equity Investor | 01/01/2024 |
Azafaros BV
 Azafaros BV Pharmaceuticals: MajorHealth Technology Develops therapeutic agents for the treatment of rare metabolic disorders | Directeur/Membre du Conseil | - |
Repronovo SA
 Repronovo SA BiotechnologyHealth Technology Develops treatments for reproductive medicine and women’s health | Directeur/Membre du Conseil | - |
Anciens postes connus de Ksenija Pavletic
| Sociétés | Poste | Fin |
|---|---|---|
Release Therapeutics SA
 Release Therapeutics SA BiotechnologyHealth Technology Develops first cell microencapsulation technology to deliver therapeutic proteins beyond the human blood-brain barrier | Directeur/Membre du Conseil | 01/11/2024 |
Merck Serono SA
 Merck Serono SA Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops drugs for reproductive and metabolism | Sales & Marketing | - |
PregLem SA
 PregLem SA Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products specializing in gynecology and women's reproductive health | Directeur Général | - |
Formation de Ksenija Pavletic
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
43
Relations au 1er degré
9
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
Webster University
 Webster University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Zagreb
 University of Zagreb Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Merck Serono SA
Merck Serono SA Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops drugs for reproductive and metabolism | Health Technology |
PregLem SA
PregLem SA Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products specializing in gynecology and women's reproductive health | Health Technology |
Release Therapeutics SA
Release Therapeutics SA BiotechnologyHealth Technology Develops first cell microencapsulation technology to deliver therapeutic proteins beyond the human blood-brain barrier | Health Technology |
Azafaros BV
Azafaros BV Pharmaceuticals: MajorHealth Technology Develops therapeutic agents for the treatment of rare metabolic disorders | Health Technology |
Jeito Capital SASU
Jeito Capital SASU Investment ManagersFinance Jeito Capital is an active manager which seeks investment opportunities in companies located in Europe. The firm targets companies operating in the fields of biotech and biopharma. It provides financing for early stage capital requirements. | Finance |
Odyssey Therapeutics, Inc.
 Odyssey Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops therapeutics for autoimmune and inflammatory diseases | Health Technology |
Repronovo SA
Repronovo SA BiotechnologyHealth Technology Develops treatments for reproductive medicine and women’s health | Health Technology |
